The effect of age at first dose on the immunogenicity of a two-dose pediatric schedule of Measles-Mumps-Rubella (MMR) or MMR-Varicella (MMRV) vaccines was assessed in children born to mostly vaccinated mothers. Immunogenicity data among children given their first measles vaccine dose between 11 and 22 months of age were pooled from five randomized controlled trials conducted in Europe and the…
Read More
Aequus Pharmaceuticals Inc. a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today that is has filed a Clinical Trial Application (“CTA”) with Health Canada in preparation for a Proof of Concept clinical study for its long-acting transdermal anti-nausea patch, AQS1303, containing the combination of pyridoxine and doxylamine (the active ingredients in Diclegis®/Diclectin®). Upon approval…
Read More
With Canada’s fast-growing tech sector facing a shortage of 220,000 workers by 2020, the federal government is right to expedite the immigration process for highly skilled workers with its new Global Talent Stream, launched June 12. As one of the CEOs from across the country who called on Ottawa to streamline the immigration process so that Canadian high-growth companies could quickly access talent in addition…
Read More
Alison McAfee is a PhD candidate working under the supervision of Dr. Leonard Foster at the University of British Columbia. Not satisfied with investigating the molecular nature of bacteria, yeast, or mammalian cells, Alison is attempting to deduce the molecular mechanism behind a type of social immunity in honey bees. We sat down with Alison to discuss her work, and…
Read More

Dina Panagiotopoulos Receives 2017 Women of Distinction Award

Congratulations to Dr. Dina Panagiotopoulos, Clinical Professor with UBC’s Faculty of Medicine, who has received a 2017 Women of Distinction Award presented by YWCA Metro Vancouver. Dr. Panagiotopoulos was recognized in the Health & Wellness category, which celebrates women who deliver, promote and advocate for healthy lives and communities. As a nationally-recognized leader in pediatric diabetes, Dr. Panagiotopoulos is also the founder and director of the Type 2…
Read More
AbCellera has entered into a collaborative research effort with Sanofi Pasteur, a global leader in the development and sale of vaccines for seasonal influenza. The project will use AbCellera’s single-cell screening platform to profile vaccine-specific human antibodies elicited by seasonal influenza vaccination and to generate large panels of human monoclonal antibodies with desired binding profiles to various influenza strains. Carl…
Read More
Every day, 43 children are diagnosed with cancer in North America. Although there have been clear improvements in the treatment of many forms of childhood cancer, the outcome for patients with recurrent or metastatic disease remains dismal and almost unchanged for decades. Moreover, current therapies have very serious side effects on the developing child. This is particularly the case for aggressive childhood cancers such as neuroblastoma, where it is essential to discover targetable alterations typical of cancer cells but which spare normal cells.
Read More
On May 15, the Faculty of Medicine celebrated the academic achievements and distinguished careers of 62 faculty members during its annual Academic Gowns and Emeriti Recognition Ceremony. From the Departments of Medicine, Physical Therapy and beyond, recipients from across the Faculty wore black gowns to mark their recent promotions to Professor, Clinical Professor or Professor of Teaching. Special recognition was…
Read More
Prof. Jim Kronstad was honoured on Thursday May 4th in a celebration commemorating his 9 years as the MSL Director. In the words of his predecessor, Prof. Phil Hieter, the event was for a man “with a lot of honour and integrity”. These heartfelt sentiments resonated throughout the afternoon as Prof. Kronstad received praise for his creativity, wisdom, strength, hard-working…
Read More
Copaxone is an efficacious and safe therapy that has demonstrated clinical benefit for over two decades in patients with relapsing forms of multiple sclerosis (MS). On an individual level, patients show variability in their response to Copaxone, with some achieving significantly higher response levels. The involvement of genes (e.g., HLA-DRB1*1501) with high inter-individual variability in Copaxone’s mechanism of action (MoA)…
Read More
"CRISPR-Cas